Amir Azadi, MD
Medical Oncology · Phoenix, AZNPI 1154615607
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Seagen Inc. at 45.6% of the total. Reporting peaked in 2023 at $12,589 and has fallen 88.5% since, to $1,443 in 2025.
Across 176 payments — averaging $141.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$11K
- Pfizer$4K
- Novocure Inc.$2K
- GT Medical Technologies, Inc$2K
- Monteris Medical Corporation$2K
- Bayer$1K
- plus $3K from 28 others
Across 55 payments — averaging $2299.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$126K
What the payments were for
- Consulting fees$9004%
- Speaking & faculty fees$14,25057%
- Travel & lodging$1,0004%
- Food & beverage$8,57934%
- Education$2261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 18 | $11,378 |
| Pfizer | 10 | $3,625 |
| Novocure Inc. | 27 | $2,010 |
| GT Medical Technologies, Inc | 11 | $1,776 |
| Monteris Medical Corporation | 18 | $1,670 |
| Bayer | 6 | $1,165 |
| AstraZeneca(2 entities) | 12 | $473 |
| AbbVie | 14 | $278 |
| E.r. Squibb & Sons, L.L.C. | 9 | $253 |
| Astellas Pharma US Inc | 8 | $217 |
| Daiichi Sankyo Inc. | 5 | $212 |
| Intuitive Surgical | 2 | $196 |
| Gilead | 3 | $172 |
| Stemline Therapeutics Inc. | 2 | $150 |
| Telix Pharmaceuticals | 1 | $141 |
| Janssen Scientific Affairs, LLC | 1 | $141 |
| Johnson & Johnson(2 entities) | 3 | $129 |
| Springworks Therapeutics, Inc. | 1 | $122 |
| Novartis | 5 | $117 |
| Portola Pharmaceuticals, LLC | 1 | $116 |
| Icotec Medical Inc. | 1 | $104 |
| Caris MPI, Inc. | 1 | $91 |
| Progenics Pharmaceuticals, Inc. | 3 | $74 |
| Menarini Silicon Biosystems, Inc. | 1 | $68 |
| Sobi, Inc | 3 | $56 |
| Eisai Inc. | 2 | $53 |
| Beone Medicines USA, Inc. | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Beigene USA, Inc. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Aspira Women's Health Inc | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,955 in reported general payments places this provider in the 75th percentile of 59 medical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 13 | $198,991 |
| EliquisApixaban | 42 | $34,109 |
| Levetiracetam | 44 | $1,133 |
| Dexamethasone | 85 | $789 |
| Anastrozole | 20 | $554 |
| Levetiracetam ErLevetiracetam | 13 | $329 |
| Memantine Hcl | 17 | $299 |
| Ondansetron Hcl | 28 | $293 |
| Oxycodone Hcl | 20 | $190 |
| Modafinil | 13 | $173 |
| Mirtazapine | 15 | $153 |
| Pregabalin | 14 | $93 |
| Temazepam | 12 | $70 |
| Sertraline Hcl | 16 | $61 |
| Citalopram HbrCitalopram Hydrobromide | 17 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,625 | $34,10942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 59 medical oncology providers in Arizona.
Other medical oncology in Phoenix
- Jason SalganickPhoenix$1.6M
- Waqas ArslanPhoenix$39K
- Amber FlahertyPhoenix$38K
- Mital PatelPhoenix$13K
- Haider ZafarPhoenix$7K
- Harshita ParipatiPhoenix$7K
- Debra WongPhoenix$6K
- Angela SaverimuthuPhoenix$1K
- Albert WendtPhoenix$474
- Vamsee TorriPhoenix$368
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.